Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
about
Development of manganese-based nanoparticles as contrast probes for magnetic resonance imagingIntracellular aggregation of multimodal silica nanoparticles for ultrasound-guided stem cell implantation.Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices.Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysisGadolinium-based contrast agent toxicity: a review of known and proposed mechanismsFour-dimensional flow magnetic resonance imaging in cirrhosis.25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future PerspectivesClinical imaging in regenerative medicineCardiovascular magnetic resonance physics for clinicians: Part II.Imaging management of incidentally detected small renal masses.New magnetic resonance imaging methods in nephrologyQuantitative parametric MRI of articular cartilage: a review of progress and open challengesCurrent tools for prediction of arteriovenous fistula outcomesEvolution of urological imagingSurveillance Imaging Following Endovascular Aneurysm RepairDesign of ProCAs (protein-based Gd(3+) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkersMolecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agentsNanotechnology and MRI contrast enhancementFunctionalized nanoporous silica for the removal of heavy metals from biological systems: adsorption and applicationVirus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicineElemental and chemically specific X-ray fluorescence imaging of biological systemsNephrogenic systemic fibrosis: a concise review for cardiologists.Magnetic resonance safety.Implementation of a comprehensive MR safety course for medical students.Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosisPerfusion MRI: the five most frequently asked technical questionsPatterns of late gadolinium enhancement in chronic hemodialysis patientsAssessment of myocardial ischemia with cardiovascular magnetic resonance.MRI-detectable nanoparticles: the potential role in the diagnosis of and therapy for chronic kidney disease.Three-dimensional electrocardiographically gated variable flip angle FSE imaging for MR angiography of the hands at 3.0 T: initial experience.Organic radical contrast agents for magnetic resonance imaging.Gadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd³⁺ to the glycosaminoglycan heparin.Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virusMacromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential?Is macrocycle a synonym for kinetic inertness in Gd(III) Complexes? Effect of coordinating and noncoordinating substituents on inertness and relaxivity of Gd(III) chelates with DO3A-like ligands.Quantitative mouse renal perfusion using arterial spin labeling.Contrast agents for MRI: 30+ years and where are we going?Absence of human herpes virus-8 (HHV8) in nephrogenic systemic fibrosis.Value of the diffusion-weighted MRI in the differential diagnostics of malignant and benign kidney neoplasms - our clinical experience.Hexameric Mn(II) dendrimer as MRI contrast agent.
P2860
Q22064299-1B11C38D-AFBF-4BD6-ACD2-C1CC37E80F98Q24595801-C2E4B3AA-28D6-4288-B748-746AB25BFD17Q24602293-BF6ECA5A-5870-4213-94D4-C993A9E25A3BQ24654124-0A362292-EF18-427E-8D52-324F16C9D755Q26751073-AFADEDC0-1187-416A-AC42-EFBFF93E2A2FQ26769606-B012B6FE-EDE4-4FFA-A204-B7018282B8DCQ26774810-39D0AB59-C71C-4148-8FD5-6991AC6600FFQ26851906-E184F042-B727-4403-90F0-7408D570C051Q26852691-F4428CF3-862A-4A29-B397-C12A61781C42Q26862876-B45C6C48-CF35-423B-9608-DC96BABDAA42Q26866166-AEB56607-EC6E-45CE-80A4-DAD86B25B5A2Q26992033-C450216E-FAA7-49AA-87C9-4C256E74106DQ27010042-11270349-4BD9-47E2-9E61-5E72F14540FBQ27692114-237A6AF2-C770-49DC-BC9C-BA3391079648Q28087405-8082DBDC-DC7E-4FF8-9F61-168F6E4215CCQ28235682-BB6AB471-704D-4578-8B1C-476CFB08332EQ28304646-E228372F-A5D7-4332-BD42-6E99D71B2E0FQ28307795-FD50288E-0ACE-43BA-906A-CE8CBA2BEFC7Q28387911-3A18434B-240B-48D4-ADF9-A91E105D9743Q28550482-85E0D556-7B73-49BB-8B32-6336C825A4A3Q28655858-1BA6C042-5722-4BEF-9653-9E14A13F15C6Q28972564-276EF120-6201-4275-8BB3-9EB792040B16Q30362015-15558C43-1153-4AE7-86C4-A26C521DA6F9Q30368767-5E8EE432-F2BB-431D-9179-38ED65C37925Q30410917-FD8CEFD2-F8D4-4691-9E0B-E182A10D7331Q30421969-20EB6181-0F4C-419F-AAC2-FC09374EF16DQ30434860-117691E9-F756-420F-9629-A8FD8C487F3AQ30441758-2229C0C5-E7C7-4EBD-BD87-CE3F27CFFFD2Q30457123-7F735EAC-2F02-4F04-9695-A71567D0A1EFQ30479812-997A653B-BE36-4B69-9704-67BC6B01C4FFQ30565003-FB41E8D0-1FB2-491D-A3B5-E8E65602600BQ30583956-457436D5-1F9C-4C0C-A6C1-DB698FCC7118Q30587267-EE675361-79F2-40B9-8483-A53BA6980E57Q30596925-83E68694-925F-423D-A975-CDAA864E56CDQ30604750-05BB4168-F41F-41AF-954C-3C51112A80D5Q30617482-5117D573-3B5C-4F47-ACEF-97913E109954Q30731463-95A44BFA-0F47-4832-BF8B-9EED2667EE28Q30847810-3B94031C-7E9E-42FF-9576-06EF589FD3E2Q30848947-EB3FF583-E475-4577-9C77-D18467DA6DA6Q30851400-8D0AB4D6-34C1-4E74-846F-4B1D9ED6D497
P2860
Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@ast
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@en
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@en-gb
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@nl
type
label
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@ast
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@en
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@en-gb
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@nl
altLabel
Gadolinium--a specific trigger ...... nephrogenic systemic fibrosis?
@en
prefLabel
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@ast
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@en
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@en-gb
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@nl
P3181
P356
P1476
Gadolinium - a specific trigge ...... nephrogenic systemic fibrosis?
@en
P2093
T. Grobner
P304
P3181
P356
10.1093/NDT/GFK062
P407
P577
2005-12-19T00:00:00Z